日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Randomized Phase III SIERRA Trial of (131)I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML

随机III期SIERRA试验,比较异基因造血干细胞移植前使用(131)I-阿帕米司单抗与常规治疗复发/难治性急性髓系白血病的疗效

Gyurkocza, Boglarka; Nath, Rajneesh; Seropian, Stuart; Choe, Hannah; Litzow, Mark R; Abboud, Camille; Koshy, Nebu; Stiff, Patrick; Tomlinson, Benjamin; Abhyankar, Sunil; Foran, James; Hari, Parameswaran; Chen, George; Al-Kadhimi, Zaid; Kebriaei, Partow; Sabloff, Mitchell; Orozco, Johnnie J; Jamieson, Katarzyna; Silverman, Margarida; Van Besien, Koen; Schuster, Michael; Law, Arjun Datt; Larkin, Karilyn; Pandit-Taskar, Neeta; Rowley, Scott D; Munshi, Pashna; Cook, Rachel; Levy, Moshe Y; Lazarus, Hillard M; Sandmaier, Brenda M; Pagel, John M; Reddy, Vijay; MacDougall, James; McNamara, Kathleen; Spross, Jennifer; Haeuber, Elaina; Vusirikala, Madhuri; Nahar, Akash; Desai, Avinash; Giralt, Sergio

Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

更正:ELEVATE-TN 研究 4 年随访结果显示,在初治慢性淋巴细胞白血病患者中,阿卡替尼联合或不联合奥妥珠单抗与奥妥珠单抗联合苯丁酸氮芥的疗效和安全性。

Sharman, Jeff P; Egyed, Miklos; Jurczak, Wojciech; Skarbnik, Alan; Pagel, John M; Flinn, Ian W; Kamdar, Manali; Munir, Talha; Walewska, Renata; Corbett, Gillian; Fogliatto, Laura Maria; Herishanu, Yair; Banerji, Versha; Coutre, Steven; Follows, George; Walker, Patricia; Karlsson, Karin; Ghia, Paolo; Janssens, Ann; Cymbalista, Florence; Woyach, Jennifer A; Ferrant, Emmanuelle; Wierda, William G; Munugalavadla, Veerendra; Yu, Ting; Wang, Min Hui; Byrd, John C

Erratum: Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia

更正:快速识别供体可提高高危急性髓系白血病首次缓解患者的生存率

Pagel, John M; Othus, Megan; Garcia-Manero, Guillermo; Fang, Min; Radich, Jerald P; Rizzieri, David A; Marcucci, Guido; Strickland, Stephen A; Litzow, Mark R; Savoie, M Lynn; Spellman, Stephen R; Confer, Dennis L; Chell, Jeffrey W; Brown, Maria; Medeiros, Bruno C; Sekeres, Mikkael A; Lin, Tara L; Uy, Geoffrey L; Powell, Bayard L; Bayer, Ruthee-Lu; Larson, Richard A; Stone, Richard M; Claxton, David; Essell, James; Luger, Selina M; Mohan, Sanjay R; Moseley, Anna; Erba, Harry P; Appelbaum, Frederick R

Overall Survival Associated with Real-World Treatment Sequences in Patients with CLL/SLL in the United States

美国慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者真实世界治疗方案与总生存期的关系

Rhodes, Joanna M; Bhandari, Naleen Raj; Khanal, Manoj; He, Dan; Abhyankar, Sarang; Pagel, John M; Hess, Lisa M; Skarbnik, Alan Z

A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML

一项随机III期研究,比较标准剂量与高剂量阿糖胞苷联合或不联合伏立诺他治疗急性髓系白血病(AML)的疗效。

Garcia-Manero, Guillermo; Podoltsev, Nikolai A; Othus, Megan; Pagel, John M; Radich, Jerald P; Fang, Min; Rizzieri, David A; Marcucci, Guido; Strickland, Stephen A; Litzow, Mark R; Savoie, M Lynn; Medeiros, Bruno C; Sekeres, Mikkael A; Lin, Tara L; Uy, Geoffrey L; Powell, Bayard L; Kolitz, Jonathan E; Larson, Richard A; Stone, Richard M; Claxton, David; Essell, James; Luger, Selina M; Mohan, Sanjay R; Moseley, Anna; Appelbaum, Frederick R; Erba, Harry P

Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors

对高危白血病或骨髓增生异常综合征患者进行单倍体相合造血干细胞移植前进行靶向放射治疗可提高长期生存率

Orozco, Johnnie J; Vo, Phuong T; Gooley, Ted A; Haaf, Robyn L; Lundberg, Sally J; Hamlin, Donald K; Wilbur, D Scott; Matesan, Manuela C; Fisher, Darrell R; Gopal, Ajay K; Green, Damian J; Pagel, John M; Sandmaier, Brenda M

Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison

在接受共价布鲁顿酪氨酸激酶抑制剂预处理的慢性淋巴细胞白血病患者中,皮托布替尼与维奈托克的疗效比较:一项匹配调整的间接比较研究

Al-Sawaf, Othman; Jen, Min-Hua; Hess, Lisa M; Zhang, Jiewen; Goebel, Benjamin; Pagel, John M; Abhyankar, Sarang; Davids, Matthew S; Eyre, Toby A

Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma

在65岁及以上复发/难治性大B细胞淋巴瘤患者中,Axicabtagene Ciloleucel与标准治疗相比的安全性和有效性

Westin, Jason R; Locke, Frederick L; Dickinson, Michael; Ghobadi, Armin; Elsawy, Mahmoud; van Meerten, Tom; Miklos, David B; Ulrickson, Matthew L; Perales, Miguel-Angel; Farooq, Umar; Wannesson, Luciano; Leslie, Lori; Kersten, Marie José; Jacobson, Caron A; Pagel, John M; Wulf, Gerald; Johnston, Patrick; Rapoport, Aaron P; Du, Linqiu; Vardhanabhuti, Saran; Filosto, Simone; Shah, Jina; Snider, Julia T; Cheng, Paul; To, Christina; Oluwole, Olalekan O; Sureda, Anna

Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial

Zandelisib 单药治疗或联合利妥昔单抗治疗复发或难治性 B 细胞恶性肿瘤患者,采用持续或间歇给药方案:一项多中心、首次患者、剂量递增和剂量扩展的 1b 期试验

Pagel, John M; Soumerai, Jacob D; Reddy, Nishitha; Jagadeesh, Deepa; Stathis, Anastasios; Asch, Adam; Salman, Huda; Kenkre, Vaishalee P; Iasonos, Alexia; Llorin-Sangalang, Judith; Li, Joanne; Zelenetz, Andrew D

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

ELEVATE-TN 研究 4 年随访结果显示,在初治慢性淋巴细胞白血病患者中,阿卡替尼联合或不联合奥妥珠单抗与奥妥珠单抗联合苯丁酸氮芥的疗效和安全性。

Sharman, Jeff P; Egyed, Miklos; Jurczak, Wojciech; Skarbnik, Alan; Pagel, John M; Flinn, Ian W; Kamdar, Manali; Munir, Talha; Walewska, Renata; Corbett, Gillian; Fogliatto, Laura Maria; Herishanu, Yair; Banerji, Versha; Coutre, Steven; Follows, George; Walker, Patricia; Karlsson, Karin; Ghia, Paolo; Janssens, Ann; Cymbalista, Florence; Woyach, Jennifer A; Ferrant, Emmanuelle; Wierda, William G; Munugalavadla, Veerendra; Yu, Ting; Wang, Min Hui; Byrd, John C